Dupilumab hyaluronidase regeneron clinical trials?

Here’s a quick, helpful overview about dupilumab (Dupixent) and hyaluronidase in Regeneron’s clinical work:

- What this is about: Hyaluronidase-enabled subcutaneous delivery uses an enzyme (recombinant human hyaluronidase, rHuPH20) to temporarily degrade hyaluronic acid in the subcutaneous tissue. This can allow larger injection volumes or faster absorption, potentially enabling different dosing schedules for biologics like dupilumab.

- Where dupilumab fits: Dupilumab is approved as a subcutaneous injection for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Some developers explore adding hyaluronidase to enable higher-dose or less-frequent SC dosing, or to improve convenience. This is an investigation rather than an approved product to date.

- Current status (as of my knowledge in 2024): There have been early-stage investigations and planning around hyaluronidase-enabled administration for dupilumab, but there is no approved dupilumab-hyaluronidase product. Trial results, if reported, have been limited and not reflected in an approved label. Details (trial IDs, results) change as new studies are completed or published.

If you want, I can look up the latest publicly listed trials and summarize:
- Trial identifiers (NCT numbers)
- Phase and study design (PK/PD, safety, dose)
- Current status (recruiting, active, completed)
- Any published results or presentations

Would you like me to fetch the most up-to-date ClinicalTrials.gov listings and any available trial results for dupilumab with hyaluronidase?